YUYUE MEDICAL(SZ:002223) ZHESHANG SECURITIES·2025-09-16 09:03Investment Rating - The investment rating for the company is "Accumulate" [7] Core Views - The company reported a revenue of 4.659 billion yuan in H1 2025, representing a year-on-year growth of 8.2%, and a net profit attributable to shareholders of 1.203 billion yuan, up 7.4% year-on-year [1] - The company is expected to see revenue and profit growth in the second half of 2025 due to demand recovery and channel expansion [1] - The overseas revenue for H1 2025 reached 607 million yuan, marking a significant year-on-year increase of 26.6% [1] Summary by Sections Growth Potential - The company anticipates continued high growth in new products such as blood glucose monitors and AEDs. In H1 2025, revenue from the blood glucose and POCT segment grew by 20%, while the AED segment saw a 31% increase [2] - The overseas channel is expanding rapidly, with H1 2025 overseas revenue growing by 26.6%, indicating significant growth potential in international markets [3] - The company is developing an integrated health management ecosystem leveraging AI, big data, and IoT technologies, which is expected to enhance user engagement and generate additional revenue [3] Profitability - The gross margin for H1 2025 was 50.4%, an increase of 0.4 percentage points year-on-year, with expectations to maintain a high gross margin due to ongoing new product launches [4] - The net profit margin for H1 2025 was 25.8%, a slight decrease of 0.2 percentage points year-on-year, but the company is expected to maintain a high net profit margin due to government subsidies and cost efficiency measures [4] Financial Forecast and Valuation - The company forecasts total revenue of 8.399 billion yuan for 2025, with a year-on-year growth of 11.02%, and a net profit of 2.001 billion yuan, reflecting a growth of 10.81% [5] - The expected earnings per share (EPS) for 2025 is 2.00 yuan, with a price-to-earnings (P/E) ratio of 19 times [5]